GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on February 13, 2024, by GSK Plc, serves as a transaction notification regarding the vesting of deferred investment awards for three Persons Discharging Managerial Responsibilities (PDMRs). The filing covers transactions executed on February 10, 2024.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific executive compensation transactions.
- Instrument: Ordinary shares of 31 1/2 pence each (ISIN: GB00BN7SWP63).
- Transaction Price: £16.60 per share.
- Total Notional Shares Involved: 114,000.36 shares across three executives.
Material Changes and Transaction Details
The filing reports the vesting of 50% of awards made on February 10, 2021, under the GlaxoSmithKline Deferred Investment Award Programme. The transactions resulted in cash payments to the executives, less applicable tax withholding, rather than the issuance of new shares.
- Deborah Waterhouse (CEO, ViiV Healthcare and President, GSK Global Health): Received a cash payment of £756,962.38 in respect of 45,600.144 notional Ordinary Shares.
- Regis Simard (President, Global Supply Chain): Received a cash payment of £378,481.19 in respect of 22,800.072 notional Ordinary Shares.
- Luke Miels (Chief Commercial Officer): Received a cash payment of £756,962.38 in respect of 45,600.144 notional Ordinary Shares.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of executive compensation events.
Key Facts for Investor Verification
- Verify the total cash outflow to executives for this specific vesting event (£1,892,405.95 gross before tax withholding).
- Confirm the share price of £16.60 used for the valuation of the notional shares against the market price on February 10, 2024.
- Note that these transactions represent cash settlements of deferred awards, not open market share purchases or sales by the executives.